Omalizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): single-center experience in 18 cases

ConclusionsOmalizumab improved asthma control in some patients with EGPA with uncontrolled asthma by reducing asthma exacerbations and oral steroid requirement. However, more data are needed before recommending widespread use of omalizumab in patients with EGPA. (Source: World Allergy Organization Journal)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2rjn8he